Wang 2006

Methods	Individually RCT
Participants	Number of participants: 214 (no dropouts mentioned) Gabon International Tropical Medicine Institute Age range: 6-60, All have P. falciparum malaria clinical symptoms and blood smear positive. 1. Trial group: 108, male 50, female 58, age 16.4 +/-10.5 2. Control group: 106, male 52, female 54, age 18.2 +/- 9.4 Exclusion criteria: N/A
Interventions	1. Artesunate IM injection, daily for 5 days, 1.2 mg/kg each dose, first dose double. PQ 3 tablets (base 7.5 mg/tablet, children use half) once a day, for 5 days. 2. Only artesunate IM injection daily for 5 days, 1.2 mg/kg each dose, the first dose double total 5 days.
Outcomes	1. Fever clearance time: (hrs) below 37°C continuously measured four times 2. Clinical cure rate at day 7 3. Adverse events (not specified) 4. Recrudescence rate: symptoms appeared again after clinical cure; parasite appeared in blood smear by 28 days Follow-up: 28 days
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stated to be randomized, and the fact that numbers per group are not equal supports this contention.
Allocation concealment (selection bias)	Unclear risk	No information given.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not stated.
Selective reporting (reporting bias)	Unclear risk	Not stated.
Other bias	Unclear risk	Unknown.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not stated to be blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated to be blinded.

AL = artemether-lumefantrine

AQ = amodiaquine

AS = artesunate

CQ = chloroquine

DHAP = dihydroartemisinin-piperaquine

G6PD = glucose-6-phosphate dehydrogenase

IM = Intramuscular

MQ = mefloquine

PCR = polymerase chain reaction

Pf = Plasmodium falciparum

PQ = primaquine

QN = quinine

RCT = randomized controlled trial

SP = sulfadoxine-pyrimethamine